Dewpoint Therapeutics

The discovery of biomolecular #condensates was an astounding breakthrough. A revelation so profound, it completely transformed the understanding of cellular function and organization. Discover how Dewpoint is exploring the relationship between condensate biology and human disease to advance therapies for diseases previously thought undruggable. https://lnkd.in/expN2ZSR #DiscoverDewpoint #biotechnology

We are honored to be a finalist at the #BWBAwards 2024! We hope to see you on the red carpet. https://bit.ly/4fliR3g

With one last game night Dewpoint style, we say farewell and wish the best of luck to our Dewpoint scientists who will be starting graduate programs this fall!   Christina Curran: MSTP (MD/PhD) program at UC Irvine Mubtasim Akhyar: Baylor College of Medicine, Chemical, Physical, and Structural Biology Program Tianna Edwards: Tufts University Biomedical Engineering Program Nora Haggerty: Biochemistry, Cellular and Molecular Biology (BCMB) PhD program at the Johns Hopkins University School of Medicine Thank you for your scientific contributions to Dewpoint, and we look forward to seeing where your careers will take you next!

Last month, two of Dewpoint's scientists, Erik Martin and Diana Mitrea took part in the Gordon Research Conference – Intrinsically Disordered Proteins, in Les Diablerets, Switzerland. The meeting brought together a diverse group of established and trainee scientists, from academia and industry to discuss the field of Intrinsically Disordered Proteins research.    The meeting covered multiple length scales, from the molecular to cellular level, as well as emerging experimental and computational methods.   "It was refreshing to see studies that integrated the relevance of structured domains and conformational features of folded and disordered regions to explain protein function and regulation, and their application for understanding fundamental concepts in biology and developing new therapeutics" – Diana Mitrea In addition to the science, the conference was an opportunity to connect with members of the scientific community. Erik was honoured to attend the associated Gordon Research Symposium for trainees as a mentor to students looking to start careers in biotech. Photo: Diana, Erik and Dewpoint Scientific Advisory Board member, Rohit Pappu.

We are pleased to share that Dewpoint has contributed an insightful article to the latest eReport on neuroscience. The article, authored by our very own Diana Mitrea, 'Leveraging the power of molecular communities' explores the groundbreaking potential of targeting biomolecular condensates for therapeutic development.   Diana discusses how our AI-powered platform is used to identify novel condensate targets, validate hypotheses, and discover and optimize c-mods (condensate-modulating drugs). This approach shows promising results in addressing complex diseases such as ALS by targeting aberrant condensates and restoring cellular function.   Dive into the details of our innovative research and its implications for future treatments here https://bit.ly/4bwh48G

At the recent ESMO - European Society for Medical Oncology GI Scientific Meeting, our Head of Translational Science, Kip West, showcased our latest advancements in targeting the elusive "undruggable" protein beta catenin. These exciting data show that beta catenin c-mods elicit robust anti-tumor activity against colorectal cancer (CRC) in vitro, ex vivo and in vivo, which correlates with changes in beta catenin localization and transcriptional activity. These findings highlight the potential for targeting aberrant beta catenin signaling through condensate modulation in the treatment of CRC to address the high unmet medical need of this disease. We're excited about the progress we've made and are eager to continue exploring this promising avenue of research. Congratulations to Kip and the entire Dewpoint team for their dedication to advancing cancer research and improving patient outcomes! 👏 Learn more about our ongoing efforts in CRC research: https://lnkd.in/efVzz3ip

🔊 Listen to Dr. Mark Murcko in our Inaugural 2024 Kitchen Table Talk! Dewpoint scientists hosted experienced drug-hunter Dr. Mark Murcko to kick off our 2024 Kitchen Table Talk series. Dr. Murcko delves into the evolution of drug discovery strategies and how adopting a condensate mindset can transform the way we develop future therapies. Check out the audiogram below for a glimpse into the discussion, and learn how insights into aberrant #condensates and their relationship to disease are reshaping our understanding of disease mechanisms and strategies for drug discovery. 👉 Watch the full discussion here: https://bit.ly/3VB9Dak #DiscoverCondensates

At last week’s International Rett Syndrome Foundation Scientific Meeting, Dewpoint scientist Marty Fernandez presented the first data from our Rett Syndrome program.   These exciting data provide new insight into a mechanism by which aberrant MeCP2 condensates contribute to the pathophysiology of Rett Syndrome and demonstrated the therapeutic potential of condensate-modifying drugs (c-mods) to selectively restore MeCP2 function and treat this complex disease.   These findings are a step forward towards the development of a disease modifying treatment for patients suffering from Rett Syndrome. Congratulations to Marty and all of the team for this fantastic work. https://lnkd.in/emF2QU5j   #Rettsyndrome #rarediseaseresearch

Exciting news! Dewpoint Therapeutics and Novo Nordisk have expanded their partnership to advance #drugdiscovery. By combining Dewpoint's high-throughput screening platform with Novo Nordisk's expertise in target discovery, the collaboration aims to unlock new therapeutic possibilities.   Read the full update on our website: https://bit.ly/3RJyAiB

Dewpoint is excited to welcome Lis Leiderman, M.D., MBA, as Chief Financial and Corporate Development Officer. As a seasoned biotech leader with 20 years experience at the intersection of medical innovation and healthcare investment banking, Lis is perfectly placed to support Dewpoint as we write our next chapter and bring condensate modifying treatments to the clinics. Lis will be a member of the Executive Leadership Team and strategic partner to the CEO, helping to shape our company for medium and long-term success. Welcome to Dewpoint, Lis! https://bit.ly/4eDINa4